Reports Q2 revenue $51.47B, consensus $50.74B. "Our second quarter results demonstrate continued momentum against our plans, led by better-than-expected performance in the Pharmaceutical segment and Medical results in-line with our prior commentary," said Jason Hollar, CEO of Cardinal Health. "With the first half of fiscal year 2023 behind us, we are pleased to raise our full year non-GAAP EPS guidance and outlook for the Pharmaceutical segment. In the Medical segment, we remain confident in our Medical Improvement Plan, including the actions we are taking to mitigate supply chain inflation and drive improved performance."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CAH:
- Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance
- Notable companies reporting before tomorrow’s open
- Cardinal Health price target raised to $91 from $78 at UBS
- Cardinal Health announces Aaron Alt as chief financial officer
- Yellow Corp appoints Annlea Rumfola as CIO
